1. Emergent immunotherapy approaches for brain metastases. (27th November 2021) Authors: Wang, Jianbo; Tawbi, Hussein A Journal: Neuro-oncology advances Issue: Volume 3(2021)Supplement 5 Page Start: v43 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. Issue 12 (December 2021) Authors: Tawbi, Hussein A; Forsyth, Peter A; Hodi, F Stephen; Algazi, Alain P; Hamid, Omid; Lao, Christopher D; Moschos, Stergios J; Atkins, Michael B; Lewis, Karl; Postow, Michael A; Thomas, Reena P; Glaspy, John; Jang, Sekwon; Khushalani, Nikhil I; Pavlick, Anna C; Ernstoff, Marc S; Reardon, David A; Ku... Journal: Lancet oncology Issue: Volume 22:Issue 12(2021) Page Start: 1692 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Issue 2 (February 2018) Authors: Amaria, Rodabe N; Prieto, Peter A; Tetzlaff, Michael T; Reuben, Alexandre; Andrews, Miles C; Ross, Merrick I; Glitza, Isabella C; Cormier, Janice; Hwu, Wen-Jen; Tawbi, Hussein A; Patel, Sapna P; Lee, Jeffrey E; Gershenwald, Jeffrey E; Spencer, Christine N; Gopalakrishnan, Vancheswaran; Bassett, R... Journal: Lancet oncology Issue: Volume 19:Issue 2(2018) Page Start: 181 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Issue 7 (July 2019) Authors: Andrews, Miles C; Berry, Donald A; Block, Matthew S; Boland, Genevieve M; Bollin, Kathryn B; Carlino, Matteo S; Carvajal, Richard D; Cohen, Jonathan; Davar, Diwakar; Delman, Keith A; Dummer, Reinhard; Farwell, Michael D; Fisher, David E; Fusi, Alberto; Glitza, Isabella C; de Gruijl, Tanja D; Gyor... Journal: Lancet oncology Issue: Volume 20:Issue 7(2019) Page Start: e378 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Nivolumab plus ipilimumab in melanoma brain metastases – Authors' reply. Issue 2 (February 2022) Authors: Tawbi, Hussein A; Eroglu, Zeynep; Anders, Carey K; Margolin, Kim A Journal: Lancet oncology Issue: Volume 23:Issue 2(2022) Page Start: e54 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. PD-1 inhibition in sarcoma still needs investigation – Authors' reply. Issue 1 (January 2018) Authors: Tawbi, Hussein A; Bolejack, Vanessa; Burgess, Melissa; Schuetze, Scott Journal: Lancet oncology Issue: Volume 19:Issue 1(2018) Page Start: e7 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Issue 11 (November 2017) Authors: Tawbi, Hussein A; Burgess, Melissa; Bolejack, Vanessa; Van Tine, Brian A; Schuetze, Scott M; Hu, James; D'Angelo, Sandra; Attia, Steven; Riedel, Richard F; Priebat, Dennis A; Movva, Sujana; Davis, Lara E; Okuno, Scott H; Reed, Damon R; Crowley, John; Butterfield, Lisa H; Salazar, Ruth; Rodriguez-... Journal: Lancet oncology Issue: Volume 18:Issue 11(2017:Nov.) Page Start: 1493 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204). Issue 11 (21st April 2021) Authors: Tawbi, Hussein A; Forsyth, Peter A; Hodi, F Stephen; Lao, Christopher D; Moschos, Stergios J; Hamid, Omid; Atkins, Michael B; Lewis, Karl; Thomas, Reena P; Glaspy, John A; Jang, Sekwon; Algazi, Alain P; Khushalani, Nikhil I; Postow, Michael A; Pavlick, Anna C; Ernstoff, Marc S; Reardon, David A; ... Journal: Neuro-oncology Issue: Volume 23:Issue 11(2021) Page Start: 1961 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i). Issue 6 (21st June 2022) Authors: Tawbi, Hussein A; Robert, Caroline; Brase, Jan C; Gusenleitner, Daniel; Gasal, Eduard; Garrett, James; Savchenko, Alexander; Görgün, Güllü; Flaherty, Keith T; Ribas, Antoni; Dummer, Reinhard; Schadendorf, Dirk; Long, Georgina V; Nathan, Paul D; Ascierto, Paolo A Journal: Journal for immunotherapy of cancer Issue: Volume 10:Issue 6(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. The Great Debate at 'Immunotherapy Bridge', Naples, December 5, 2019. Issue 2 (24th August 2020) Authors: Ascierto, Paolo A; Bifulco, Carlo; Galon, Jerome; Garbe, Claus; Khleif, Samir N; McQuade, Jennifer; Odunsi, Kunle; Okada, Hideho; Paulos, Chrystal M; Quezada, Sergio A; Tawbi, Hussein A; Timmerman, John; Trinchieri, Giorgio; Butterfield, Lisa H; Puzanov, Igor Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗